Even though epidemiological and experimental evidence supports a direct involvement of VP in insulin resistance-associated disorders, to date nothing is known about the role of circulating copeptin in human NAFLD and NASH. This evidence concerns the gene AVP and metabolic dysfunction-associated steatohepatitis.